The old uses were specific
The drug agency’s name is Food and Drug Administration; FDA is its short form.
Sermorelin (Geref) had FDA approvals for a test of growth hormone release and for children with growth failure due to a hormone shortage.
Those approvals ended on June 18, 2009; there was no marketed FDA-approved sermorelin product in September 2026.
Its past approvals did not cover adult sleep, energy, body shape or ageing.
Leaving the market did not settle every question
The FDA’s 2013 finding says safety and effectiveness were not the reasons Geref was withdrawn.
That finding concerns the discontinued product; it does not endorse a medicine offered today.
Which claim is about the old product, and which is about the medicine in this offer?
A pharmacy-made medicine has its own conditions
The full ingredient name is sermorelin acetate; “acetate” names a particular chemical form of sermorelin. The pharmacy rules described here concern that form, not every ingredient sold as sermorelin.
As of September 2026, a licensed pharmacy may be able to prepare sermorelin acetate for a named patient with a prescription.
Every other applicable federal and state requirement still has to be met.
Having a pharmacy make a medicine, called compounding, does not give that medicine FDA approval.
Does the ingredient name in this offer say “sermorelin acetate”, and what rules must the pharmacy follow to make it?